The regulatory authorities in the individual countries are to implement this decision within 30 days by granting domestic approvals.
The first domestic approvals for Oracea(r) will be granted in Germany, the UK, Italy, Austria, Ireland, Sweden, Finland, Luxembourg, and the Netherlands.